Curemark LLC, a Rye, N.C.-based drug research and development company, closed a $20m in equity financing from the Frist Family.
William and Jennifer Frist joined Curemark’s Board of Directors.
The company intends to use the funds for growth and expansion.
Led by Dr. Joan Fallon, founder and CEO, Curemark focuses on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies.
The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints.
FinSMEs
13/07/2015